

Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-Aug-2023  
Document Type: USP Monographs  
DocId: GUID-ABAFA796-6721-4769-8BAE-A3BF1946E0D1\_4\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M44950\\_04\\_01](https://doi.org/10.31003/USPNF_M44950_04_01)  
DOI Ref: tn6qj

© 2025 USPC  
Do not distribute

## Levorphanol Tartrate Tablets

### DEFINITION

Levorphanol Tartrate Tablets contain NLT 93.0% and NMT 107.0% of the labeled amount of levorphanol tartrate ( $C_{17}H_{23}NO \cdot C_4H_6O_6 \cdot 2H_2O$ ).

### IDENTIFICATION

- A.

**Sample:** Nominally equivalent to about 1 mg of levorphanol tartrate from a number of finely powdered Tablets

**Analysis:** To the *Sample*, add 1 mL of [water](#), 1 drop of 3 N hydrochloric acid, and 2 drops of [ferric chloride TS](#), and heat to boiling. To the hot solution, add 1 mL of [potassium ferricyanide](#) solution (1 in 200).

**Acceptance criteria:** A bluish color develops.

- B.

**Sample solution:** Powder a number of Tablets, equivalent to about 60 mg of levorphanol tartrate, and transfer the mixture to a small separator. Add 10 mL of [water](#), dissolve as much of the powder as possible, add about 400 mg of [sodium bicarbonate](#), and extract with a 50-mL portion of [chloroform](#). Evaporate the filtered chloroform extract on a steam bath to a small volume, and dilute with [chloroform](#) to 10 mL.

**Analysis:** Determine the angular rotation of the *Sample solution* (see [Optical Rotation \(781\)](#)).

**Acceptance criteria:** The *Sample solution* is levorotatory.

### ASSAY

- PROCEDURE

**Sample solution:** Weigh and finely powder Tablets (NLT 20). Transfer an amount nominally equivalent to about 40 mg of levorphanol tartrate to a 125-mL separator. Add 20 mL of [water](#) and sufficient [sodium bicarbonate](#) to render the suspension alkaline to litmus. Add an additional 100 mg of [sodium bicarbonate](#), and extract the levorphanol with five 20-mL portions of a mixture of 3 volumes of ether and 1 volume of [chloroform](#). Pass the combined extracts through a layer of about 10 g of granular [sodium sulfate, anhydrous](#) into a 500-mL conical flask, and evaporate to a volume of about 30 mL.

#### Titrimetric system

**Mode:** Direct titration

**Titrant:** 0.01 N perchloric acid in dioxane VS

**End point detection:** Visual

**Analysis:** To the *Sample solution*, add about 50 mL of [chloroform](#) and 1 drop of [methyl red TS, methanolic](#). Titrate with the *Titrant* to a red endpoint. Perform a blank determination, and make any necessary correction. Each milliliter of 0.01 N perchloric acid is equivalent to 4.435 mg of levorphanol tartrate ( $C_{17}H_{23}NO \cdot C_4H_6O_6 \cdot 2H_2O$ ).

**Acceptance criteria:** 93.0%–107.0%

### PERFORMANCE TESTS

- [DISSOLUTION \(711\)](#)

**Medium:** [Water](#) 500 mL

**Apparatus 2:** 50 rpm

**Time:** 30 min

**Standard solution:** A known concentration of [USP Levorphanol Tartrate RS](#) in *Medium*

**Sample solution:** Pass a portion of the solution under test through a filter and suitably dilute with [water](#).

#### Instrumental conditions

**Mode:** UV

**Analytical wavelength:** Maximum absorbance at about 279 nm

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Determine the percentage of levorphanol tartrate ( $C_{17}H_{23}NO \cdot C_4H_6O_6 \cdot 2H_2O$ ) dissolved by comparing the UV absorbances between the

*Standard solution* and *Sample solution*.

**Tolerances:** NLT 75% (Q) of the labeled amount of levorphanol tartrate ( $C_{17}H_{23}NO \cdot C_4H_6O_6 \cdot 2H_2O$ ) is dissolved.

#### Change to read:

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): ▲Meet the requirements ▲ (CN 1-Aug-2023)

**Procedure for content uniformity****Diluent:** 0.1 N hydrochloric acid**Standard solution:** [USP Levorphanol Tartrate RS](#) in *Diluent* having a known concentration of about 80 µg/mL of anhydrous levorphanol tartrate**Sample solution:** Nominally about 80  $\mu\text{g}$  /mL of levorphanol tartrate in *Diluent* prepared as follows. Transfer 1 Tablet to a glass-stoppered flask, add 25.0 mL of *Diluent*, and allow the Tablet to disintegrate. Shake well, filter through a small filter paper, and discard the first portion of the filtrate. Dilute a portion of the filtrate quantitatively and stepwise, if necessary.**Instrumental conditions****Mode:** UV**Analytical wavelength:** Maximum absorbance at about 279 nm**Blank:** *Diluent***Cell:** 1 cm**Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of the labeled amount of levorphanol tartrate ( $\text{C}_{17}\text{H}_{23}\text{NO} \cdot \text{C}_4\text{H}_6\text{O}_6 \cdot 2\text{H}_2\text{O}$ ) in the portion of Tablets taken:

$$\text{Result} = (A_u/A_s) \times (C_s/C_u) \times (M_{r1}/M_{r2}) \times 100$$

 $A_u$  = absorbance of the *Sample solution* $A_s$  = absorbance of the *Standard solution* $C_s$  = concentration of [USP Levorphanol Tartrate RS](#), on the anhydrous basis, in the *Standard solution* (µg/mL) $C_u$  = nominal concentration of levorphanol tartrate in the *Sample solution* (µg/mL) $M_{r1}$  = molecular weight of the hydrated form of levorphanol tartrate, 443.49 $M_{r2}$  = molecular weight of the anhydrous form of levorphanol tartrate, 407.47

▲ (CN 1-Aug-2023)

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.
- [USP REFERENCE STANDARDS \(11\)](#)  
[USP Levorphanol Tartrate RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question               | Contact                                       | Expert Committee          |
|------------------------------|---|---------------------------|
| LEVORPHANOL TARTRATE TABLETS | <a href="#">Documentary Standards Support</a> | SM22020 Small Molecules 2 |

**Chromatographic Database Information:** [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. Information currently unavailable

**Current DocID: GUID-ABAFA796-6721-4769-8BAE-A3BF1946E0D1\_4\_en-US****DOI:** [https://doi.org/10.31003/USPNF\\_M44950\\_04\\_01](https://doi.org/10.31003/USPNF_M44950_04_01)**DOI ref:** [tn6qj](#)